Survival of Older Patients With Cancer in the Veterans Health Administration Versus Fee-for-Service Medicare
- 1 April 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (10), 1072-1079
- https://doi.org/10.1200/jco.2011.35.6758
Abstract
Purpose The Veterans Health Administration (VHA) provides high-quality preventive chronic care and cancer care, but few studies have documented improved patient outcomes that result from this high-quality care. We compared the survival rates of older patients with cancer in the VHA and fee-for-service (FFS) Medicare and examined whether differences in the stage at diagnosis, receipt of guideline-recommended therapies, and unmeasured characteristics explain survival differences. Patients and Methods We used propensity-score methods to compare all-cause and cancer-specific survival rates for men older than age 65 years who were diagnosed or received their first course of treatment for colorectal, lung, lymphoma, or multiple myeloma in VHA hospitals from 2001 to 2004 to similar FFS-Medicare enrollees diagnosed in Surveillance, Epidemiology, and End Results (SEER) areas in the same time frame. We examined the role of unmeasured factors by using sensitivity analyses. Results VHA patients versus similar FFS SEER-Medicare patients had higher survival rates of colon cancer (adjusted hazard ratio [HR], 0.87; 95% CI, 0.82 to 0.93) and non–small-cell lung cancer (NSCLC; HR, 0.91; 95% CI, 0.88 to 0.95) and similar survival rates of rectal cancer (HR, 1.05; 95% CI, 0.95 to 1.16), small-cell lung cancer (HR, 0.99; 95% CI, 0.93 to 1.05), diffuse large–B-cell lymphoma (HR, 1.02; 95% CI, 0.89 to 1.18), and multiple myeloma (HR, 0.92; 95% CI, 0.83 to 1.03). The diagnosis of VHA patients at earlier stages explained much of the survival advantages for colon cancer and NSCLC. Sensitivity analyses suggested that additional adjustment for the severity of comorbid disease or performance status could have substantial effects on estimated differences. Conclusion The survival rate for older men with cancer in the VHA was better than or equivalent to the survival rate for similar FFS-Medicare beneficiaries. The VHA provision of high-quality care, particularly preventive care, can result in improved patient outcomes.Keywords
This publication has 38 references indexed in Scilit:
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningThe New England Journal of Medicine, 2011
- Systematic ReviewMedical Care, 2011
- Quality of Nonmetastatic Colorectal Cancer Care in the Department of Veterans AffairsJournal of Clinical Oncology, 2010
- Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon CancerJama-Journal Of The American Medical Association, 2010
- Adverse Events Among the Elderly Receiving Chemotherapy for Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Differences in Clinical Trial Patient Attributes and Outcomes According to Enrollment SettingJournal of Clinical Oncology, 2010
- Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancerLung Cancer, 2004
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaThe New England Journal of Medicine, 1993
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Reducing Bias in Observational Studies Using Subclassification on the Propensity ScoreJournal of the American Statistical Association, 1984